Compare OLPX & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OLPX | RGNX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 680.9M | 661.2M |
| IPO Year | 2021 | 2015 |
| Metric | OLPX | RGNX |
|---|---|---|
| Price | $1.25 | $13.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $1.81 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 1.1M | 616.1K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $418,582,000.00 | $161,318,000.00 |
| Revenue This Year | $2.15 | $132.80 |
| Revenue Next Year | $2.31 | $48.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 91.30 |
| 52 Week Low | $0.99 | $5.04 |
| 52 Week High | $2.28 | $13.93 |
| Indicator | OLPX | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 66.34 | 59.81 |
| Support Level | $1.10 | $12.05 |
| Resistance Level | $1.20 | $13.77 |
| Average True Range (ATR) | 0.06 | 0.80 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 94.60 | 77.74 |
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.